AFP and hepatocellular carcinoma: Since AFP is an important clinical tumor marker for HCC growth and aggressiveness, we examined the effects of GSK1838705A and OSI-906 on Regorafenib/VK1-mediated inhibition of AFP secretion levels after 48 h, using the two AFP-secreting human HCC cell lines, PLC/PRF/5 and HepG2.